Boehringer Biochemia Robin S.p.a.

Boehringer Mannheim Italia

Dompé Farmaceutici S.p.a.

Dompe S.p.a.

Other

Dompe Pha.r.ma S.p.a.

Dimpe' Spa

Beehringer Biochemia Robin S.p.a.

Carmelo A Gandolfi

Sergio Tognella

Odoardo Tofanetti

Silvano Spinelli

Marco Frigerio

Gianfranco Caselli

Marcello Allegretti

Marco Mantovanini

Maria Candida Cesta

Riccardo Bertini

Cinzia Bizzarri

Francesco Colotta

Gaetano Clavenna

Roberto Di Domenico

Andrea Zaliani

Carlo Riva

Licia Gallico

Giorgio Long

Vilma Sabbatini

Ernesto Menta

Franco Zunino

Alessandro Pasini

Bruno Lumachi

Maria Carla Gandolfi, Legal Representative

Arrigo Aldo Gandolfi, Legal Representative

Vito Di Cioccio

Janete Peloia Barroso Gandolfi, Legal Representative

Giulio Agostino Gandolfi, Legal Representative

Claudio Omini

Stefano Porzio

Lorella Cotini

Raimondo Russo

Valerio Berdini

Giorgio Cignarella

Enrico Bosone

Antonella Rozzi

Ginfranco Caselli

Giampiero De Cillis

Roberto Curti

Gianpiero De Cillis

Sengio Tognella

Francis Johnson

Roberto D Domenico

Simonetta Fiorentino

Piervitto Cipolla

PierVitto Cipolla

Sergio Tongnella

Daniele Castoldi

Fracesco Colotta

Mauro Germini

(R)-2-Arylpropionamide compounds of formula (I), pharmaceutical preparations of the compounds and a process for making the compounds are described. The 2-Arylpropionamides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbated recruitment of polymorphonuclear leukocytes and monocytes at inflammatory sites. In particular, the invention relates to the R enantiomers of omega-aminoalkylamides of 2-aryl propionic acids, of formula (I), for use as inhibitors of chemotaxis of neutrophils and monocytes induced by the C5a fraction of complement and by other chemotactic proteins whose biological activity is associated with activation of a 7-TD receptor. Selected compounds of formula (I) are dual inhibitors of both the C5a-induced chemotaxis of neutrophils and monocytes and the IL-8-induced chemotaxis of polymorphonuclear leukocytes.

Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells

(R)-2-Arylpropionamide compounds of formula (I) are described. The process for their preparation and pharmaceutical preparations thereof are also described. The 2-Arylpropionamides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbate recruitment of polymorphonuclear leukocytes (leukocytes PMN) and of monocytes at the inflammatory sites. In particular, the invention relates to the R enantiomers of omega-aminoalkylamides of 2-aryl propionic acids, of formula (I), for use in the inhibition of the chemotaxis of neutrophils and monocytes induced by the C5a fraction of the complement and by other chemotactic proteins whose biological activity is associated with activation of a 7-TD receptor. Selected compounds of formula (I) are dual inhibitors of both the C5a-induced chemotaxis of neutrophils and monocytes and the IL-8-induced chemotaxis of PMN leukocytes. The compounds of the invention are used in the treatment of psoriasis, ulcerative cholitis, glomerular nephritis, acute respiratory insufficiency, idiopathic fibrosis, rheumatoid arthritis and in the prevention and the treatment of injury caused by ischemia and reperfusion.

Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells

N-(2-aryl-propionyl)-amides of formula (I) are described.  The process for their preparation and pharmaceutical preparations thereof are also described. The amides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbate recruitment of polymorphonuclear neutrophils (leukocytes PMN) at the inflammatory sites. In particular, the invention relates to the R enantiomers of N-(2-aryl-propionyl)amides of formula (I) for use in the inhibition of the chemotaxis of neutrophils induced by IL-8. The compounds of the invention are used in the treatment of psoriasis, ulcerative cholitis, glomerular nephritis, acute respiratory insufficiency, idiopathic fibrosis, and rheumatoid arthritis.

Amides, useful in the inhibition of IL-8-induced chemotaxis of neutrophils

The compounds of formula 1wherein R and Rare as defined in the disclosure, are useful in the prevention and treatment of tissue damage due to exacerbated recruitment of polymorphonuclear neutrophils (PMN leukocytes) at the inflammatory sites.

N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them

The compounds of formula 1,wherein R and Rare as defined in the disclosure, are useful in the prevention and treatment of tissue damage due to exacerbated recruitment of polymorphonuclear neutrophils (PMN leukocytes) at the inflammatory sites.

Compounds of formula I: ##STR1## wherein R.sub.a, R.sub.b, .PHI., B and R are as defined in the disclosure, have antagonistic activity on osteoclast hyper-reactivity.

Geminal carboxylic acids and esters thereof pharmaceutical formulations

Salts of 2-(3-benzoylphenyl) propionic acid with organic bases and

Tartronic acid acetalic ethers and esters of the general formula: ##STR1## are provided and are useful in treatment of bone dysmetabolism. As examples, Ra and Rb may be hydrogen, B is a C.sub.2 -C.sub.12 acyl group, R is phenyl and n is 0-12.

Tartronic acids, their acetalic ethers and o-esters

Tartronic acids, their acetalic ethers and O-esters

Heterocyclic amines useful in the therapy of asthma and imflammation of

[3H,7H]thiazolo[3,4-a]pyridines with antiasthmatic and antiinflammatory

Process for preparation of enantiomerically pure polysubstituted

.beta.-carbonyl-carboxyamides of 1,3-thiazolidines

Compounds of formula I are described, ##STR1## wherein: R.sub.1 and R.sub.2, that can be the same or different, are hydrogen or acyl groups;

1,4-bis(alkylamino)-2,3-diaza-anthracene-9,10-diones

Amino anthracenediones-bis platinum complexes, useful as antitumoral

Growing community of inventors

Milan, Italy

Carmelo A Gandolfi